Datapoint: Supreme Court Cements Vascepa Patent Loss

The United States Supreme Court on Monday declined to hear Amarin’s arguments against patent loss for its fish oil derivative drug Vascepa. A federal appeals court in September upheld a lower court ruling that definitively invalidates the patent, meaning generic challengers, including one from Hikma Pharmaceuticals, can move forward. Amarin had blockbuster hopes for the heart drug, which the FDA approved in December 2019. Vascepa currently holds preferred status for 33% of all covered lives under the pharmacy benefit, growing to 52% with utilization management restrictions. The drug holds covered or better status for 94% of all insured lives.

SOURCE: MMIT Analytics, as of 6/23/21

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
January 26

Datapoint: Elevance Health to Acquire BCBS Louisiana

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
January 25

Datapoint: Seagen Scores Colorectal Cancer Nod for Tukysa

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
January 24

Datapoint: Georgia Doubles Down on Partial Medicaid Expansion Waiver

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today